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1 Introduction
In trials designed to evaluate the efficacy of an intervention to prevent perinatal mother to
child transmission (PMTCT) of human immunodeficiency virus (HIV), the primary endpoint
is often the cumulative transmission rate at a point in time shortly after birth. To determine
HIV status, the infants are usually tested within 48 hours after birth to assess in utero
transmission. A second visit is often scheduled 4 to 8 weeks after birth to assess intrapartum
transmission. Subsequent visits may be scheduled, but tests at these visits only contribute
information about the primary endpoint if the infant has missed earlier scheduled visits. If
infants are tested at both scheduled visit times, estimation of the endpoint is straightforward,
as are regression models for the endpoint. Unfortunately, missed visits and off-schedule visits
are not uncommon. And, even if there are no missed visits, interim analyses may occur when
only a fraction of the infants are old enough for the second visit.
In this paper, we propose a censored multinomial regression model for analyzing PMTCT
of HIV. The approach is motivated by the HIV Prevention Trials Network (HPTN) 024 study,
a multi-site placebo-controlled trial of antiobiotics to prevent chorioamnionitis and, therefore,
perinatal transmission of HIV. From the first two testing windows, there were three main
outcomes of scientific interest:
A1 The in utero transmission rate, estimated by the fraction of infants testing positive
shortly after birth;
A2 The perinatal transmission rate, estimated by the fraction of infants testing positive
by 6 weeks (which we extended to 8 weeks, for analysis purposes);
A3 The intrapartum transmission rate, estimated by the fraction of infants testing positive
by the end of the perinatal transmission window, given they had a negative test result
at birth.
In primary analyses, we are usually interested in obtaining unadjusted estimates of A1,
A2, and A3. In this manuscript, we focus on secondary analyses, where adjusted estimates
are often desired. Ideally, every subject would be tested in every visit window, and we could
use a binary endpoint approach such as logistic regression to model all three outcomes of
scientific interest. However, we rarely have complete test result data in PMTCT clinical
trials. For example, in HPTN 024, of the 2052 liveborn infants, 1813 (88%) had HIV tests
within 48 hours of delivery, 1696 (83%) had tests 4 to 8 weeks after delivery, and only 1584
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(77%) had tests both within 48 hours of delivery and 4 to 8 weeks after delivery. While
missed visits may be due to the infant’s death (which can be accounted for), in some cases
the mother simply forgets or is unable to bring the infant in for follow-up. Often, mothers
do not deliver at the study hospital and must bring the infant in at a later point in time
for the HIV test. Such missed and off-schedule visits make the usual analytical methods
problematic.
Table 1 lists a selection of primary papers from trials aimed at reducing PMTCT of HIV
and summarizes the methods used for unadjusted and adjusted analyses, as well as how the
data were censored in each case. The methods represented are among the more commonly
used for estimating PMTCT of HIV. In adjusted analyses, the endpoint is generally modeled
as either binary or right-censored continuous, using logistic or Cox proportional hazards
(PH) regression, respectively. For both logistic and Cox PH models, methods currently
used for handling missing data may be inadequate. For example, when the logistic model
is used and a test result is missing for an infant who has not previously tested positive, the
observation is dropped, although if subsequent tests are negative, the missing test result
may be imputed to be negative. When the Cox PH model is used, an infant’s time to HIV
infection is right censored at his or her last negative test; however, approaches for addressing
the timing of infection when a missing visit is followed by a positive test and there have been
no previous positive tests may be inadequate. Some authors use the time of the first positive
test as the time of infection while others use the midpoint between the last negative and the
first positive tests (or birth and the first positive test) as the time of infection. Instead, we
propose a method that reflects the intention of the studies to classify infections according to
their timing (in utero, peripartum and postpartum) using a multinomial model. The model
accommodates incomplete longitudinal observations by allowing general censoring and also
accommodates regression on the three outcomes of interest (A1-A3).
This manuscript proceeds as follows. In Section 2, we describe the censored multinomial
model and estimation of the parameters for a single sample. In Section 3, we lay out several
strategies for adjusting for covariates. In doing so, we consider estimation for all three
scientific endpoints of interest. In Section 4, we describe simulations designed to evaluate
the performance of the proposed regression estimators. In Section 5, we present an example
based on HPTN 024. Discussion follows in Section 6.
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Table 1: Approaches taken in selected papers analyzing PMTCT of HIV
Unadjusted Adjusted Censoring
Wiktor et al. (1999) KMa – at last negative test
Guay et al. (1999) KM PHb at last negative test
Dabis et al. (1999) KM PH not stated
Shaffer et al. (1999) KM logistic regression not stated
Fawzi et al. (2000) Chi-square tests PH not stated
Dorenbaum et al. (2002) Fisher’s exact tests logistic regression –
Moodley et al. (2003) KM PH at last follow-up
and logistic regression
aKaplan-Meier.
bCox proportional hazards.
2 Estimation for a Single Sample
In this section, we present the censored multinomial model and maximum likelihood methods
for parameter estimation with a single sample. In this general presentation, we assume that
there are J visit windows. Usually, when estimating PMTCT, J = 2. However, depending
upon the study design, J may be larger as in Wiktor et al. (1999), where J = 3.
We begin by dividing the follow-up time into windows as follows:
First visit window [t11, t12)
Second visit window [t21, t22)
...
Time following last visit window [tJ+1,1,∞).
Here, J is the number of visit windows of interest, and tj1 and tj2 indicate the times at
which the jth visit window starts and ends, respectively. These intervals do not have to
be and usually are not contiguous. In other words, tj2 is not necessarily equal to tj+1,1.
Unscheduled or off-schedule visits result in tests that occur in the interval [tj2, tj+1,1). An
example of potential visit windows is shown in Figure 1 for four subjects A, B, C, and D.
In this example, J = 4.
We define a complete response vector for the ith subject as Y ∗i = (Y
∗
i1, . . . , Y
∗
iJ)
′ where
Y ∗ij = 1, j = 1, . . . , J , if the subject tests positive for the first time at the jth visit and 0
otherwise. The vector Y ∗i represents a multinomial response as the ith subject can only test
positive for HIV for the first time once. When a subject misses a scheduled visit (including
3
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Figure 1: Example of possible scheduling of testing visits.
if he or she is late or early for the visit), we observe a censored version of Y ∗i . Let Yi denote
the observed endpoint, which is defined as
Yi1 =

1, tpi ∈ [0, t12)
1, tpi ≥ t12 and tni < t11
0, otherwise
(1)
Yij =

1, tpi ∈ [tj−1,2, tj2)
1, tpi ≥ tj2 and tni < tj1
0, otherwise
, j = 2, . . . , J, (2)
Yi,J+1 =
 1, t
p
i ≥ tJ2
0, otherwise
. (3)
Here, tpi and t
n
i are the time of the first positive test result for subject i and the time of
the last negative test result for subject i, respectively. For subjects with no positive test
result during follow-up, we take tpi equal to ∞. For subjects with no negative test result
during follow-up, we take tni equal to -∞. We assume that each subject has at least one
(non-missing) test result during the follow-up period.
To illustrate how the observed vector Y relates to the unobserved but true outcome Y ∗,
we look at four possible visit and outcome patterns. Following Figure 1, we assume that the
visit windows are not contiguous. First, we examine the effect of a missed visit. Suppose
subject A is not tested until the second visit at which point he or she tests positive. We do
not know if subject A would have tested positive had he or she come in for the first visit.
We can say, however, that the subject would have tested positive for the first time at the
first visit or at the second visit if tested at both visits. In other words, Y ∗ for this subject
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may be (0, 1)′ or (1, 0)′ but is not (0, 0)′. Therefore, by (1), (2), and (3), Y = (1, 1, 0)′.
Next, we consider subject B who missed the first visit and tested negative at the second
visit. Here we assume that, if a subject tests negative at the end of the study, he or she was
negative throughout the study; therefore, Y ∗ = (0, 0)′ and Y = (0, 0, 1)′ for this subject. In
this case, even though the subject was not tested in every visit window, we have complete
information regarding his or her outcome. This illustrates another difficulty involving missed
visits. If a subject is uninfected and misses all visits except the last (the Jth visit), we still
have complete information about him or her (as in B); however, if the subject is infected at
the last visit (as in A), we have incomplete information about him or her. Returning to the
example, we also have complete information for subjects C and D, for whom Y ∗ = (0, 0)′
and Y ∗ = (0, 1)′, corresponding to Y = (0, 0, 1)′ and Y = (0, 1, 0)′, respectively.
Letting Jj be a vector of length J with jth element equal to 1 and all other elements equal
to zero, we define the probability that a subject’s first positive test occurs in the jth visit
window as pj = P (Y
∗
i = Jj), j = 1, . . . , J , and the probability that a subject’s first positive
test occurs after the last visit window as pJ+1 = 1−∑Jj=1 pj. Each subject’s contribution to
the likelihood is given by
f(yi) = Y
′
i p,
where p = (p1, . . . , pJ+1)
′. The log-likelihood can be written as
l(p1, . . . , pJ) =
N∑
i=1
log
[ J∑
j=1
Yijpj + Yi,J+1(1−
J∑
j=1
pj)
]
, (4)
where the outer summation is over all individuals in the sample. Maximum likehood esti-
mates of p1, . . . , pJ , denoted pˆ = (pˆ1, . . . , pˆJ)
′, are obtained by maximizing (4) using numer-
ical optimization techniques. In this maximization, probabilities p1, . . . , pJ are constrained
to lie between 0 and 1 and
∑J
j=1 pj is constrained to be less than 1.
We focus now on estimating the cumulative probabilities of transmission at the birth and
4 to 8 week visits. These correspond to the in utero and perinatal endpoints (A1 and A2)
described in Section 1. The birth transmission rate, P1, is estimated by P̂1 = pˆ1. The 4 to 8
week transmission rate, P2 = p1 +p2, is estimated by P̂2 = pˆ1 + pˆ2. In general, the cumulative
transmission rate is obtained as Pj =
∑j
k=1 pk, j ≤ J , with maximum likelihood estimate
P̂j =
∑j
k=1 pˆk. By the multivariate delta method (Agresti, 2002, page 579), the asymptotic
variance of P̂j is given by vj =
∑j
k=1
∑j
l=1 Vkl, where Vkl denotes the element in the kth row
and lth column of V , the covariance matrix of pˆ1, . . . , pˆJ . We estimate V using the negative
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of the inverse of the Hessian matrix.
We turn now to consider endpoint A3, the intrapartum transmission rate. The intra-
partum transmission rate represents the probability that an infant is infected during delivery
and is given by
p2|1− =
p2
1− p1 .
We estimate p2|1− as the fraction of infants who test positive by the end of the second visit
window given that they had a negative test result at birth. That is, we estimate p2|1− as
p̂2|1− =
pˆ2
1− pˆ1 .
In a breastfeeding population, where HIV transmission may also occur via breastfeeding,
p̂2|1− represents the rate of delivery or early postnatal transmission.
Using the multivariate delta method, we derive the asymptotic variance of p̂2|1− as
w = (
p2
(1− p1)2 )
2 × var(pˆ1) + 2p2
(1− p1)3 × cov(pˆ1, pˆ2) +
1
(1− p1)2 × var(pˆ2).
We estimate this quantity using
wˆ = (
pˆ2
(1− pˆ1)2 )
2 × v̂ar(pˆ1) + 2pˆ2
(1− pˆ1)3 × ĉov(pˆ1, pˆ2) +
1
(1− pˆ1)2 × v̂ar(pˆ2),
where v̂ar(pˆ1), ĉov(pˆ1, pˆ2), and v̂ar(pˆ2) are obtained using the negative of the inverse of the
Hessian matrix.
In the case where there are more than two visit windows, we can denote the probability
of testing positive at the jth visit given that the first j − 1 tests are negative as
pj|(j−1)− = Pr {Y ∗i = Jj|Y ∗i 6= J1, . . . ,Jj−1} ,
which can be written as
pj = pj|(j−1)− × (1−
j−1∑
k=1
pk).
The asymptotic variance of ̂pj|(j−1)− is given by
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wj =
j−1∑
l=1
j−1∑
l′=1
[
(
pj
(1−∑j−1k=1 pk)2 )
2 × Vll′
]
+2
j−1∑
l′=1
[ pj
(1−∑j−1k=1 pk)3 × Vjl′
]
+
1
(1−∑j−1k=1 pk)2 × Vjj. (5)
Here, Vll′ denotes the element in the lth row and l
′th column of V, the covariance matrix
of pˆ1, . . . , pˆJ . Vjl′ denotes the element in the jth row and l
′th column of V, and Vjj denotes
the element in the jth row and jth column of V. We use the negative of the inverse of the
Hessian matrix to estimate Vll′ , Vjl′ , and Vjj. We substitute these estimates, with pˆ1, . . . , pˆj,
into (5) to obtain estimates of wj.
3 Regression Approaches
In the previous section, we presented methods for estimating one sample or unadjusted
probabilities of HIV transmission, corresponding to endpoints A1 through A3. In this section,
we use a regression approach to determine how cumulative and conditional probabilities are
associated with predictors. In the spirit of assessing PMTCT of HIV, models are presented
for the case of two visit windows, birth and 4 to 8 weeks. We also address how these models
can be extended to analyze data from studies with more than two visit windows.
3.1 Cumulative Probabilities
We define the probability that subject i’s first positive test occurs in the jth visit window as
piij and the probability that subject i’s first positive test occurs after the last visit window
as pii,J+1 = 1 − ∑Jj=1 piij. Unlike in the previous section, here we do not assume that the
probability of testing positive for the first time in the jth visit window is the same for all
subjects. To examine the relationship between a set of predictors, (Xi1, . . . , Xim), and the
probability that subject i tests positive at or before the jth visit, we define the following
regression model:
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g(pii1) = X
′
iβ1 (6)
g(
j∑
k=1
piik) = X
′
iβj , j = 2, . . . , J, (7)
where g(·) is a link function that specifies the relationship between the predictors, Xi =
(1, Xi1, . . . , Xim)
′, and the response, through the parameter vector βj = (βj0, . . . , βjm)′, of
length m+1. For ease of exposition, we assume that a predictor is relevant for all visit
windows. Therefore, if a predictor is included in the model, it is included for all regressions.
When modeling cumulative probabilities, two appropriate choices for the link function are
the log link, where g(p) = log(p), and the logit link, where g(p) = logit(p) = log{p/(1− p)}.
Here, we focus on the logit link, where βjl, l = 1 . . . ,m, is interpreted as the change in the
log odds of testing positive at or before the jth visit window per one unit increase in Xil,
l = 1, . . . ,m.
We consider the case of two visit windows, corresponding to birth and 4 to 8 weeks. The
regression model is defined as
logit(pii1) = X
′
iβ1
logit(pii1 + pii2) = X
′
iβ2,
where β1 and β2 are parameter vectors of length m + 1 linking the predictors to the odds
of testing positive at the birth visit and the odds of testing positive at or before the 4 to 8
week visit, respectively.
Returning to the general case, we combine and re-write equations (6) and (7) to obtain
the following expressions for piij:
pii1 = g
−1(X ′iβ1) (8)
piij = g
−1(X ′iβj)− g−1(X ′iβj−1) , j = 2, . . . , J. (9)
The log-likelihood is given by
l(pii1, . . . , piiJ) =
N∑
i=1
log
[ J∑
j=1
Yijpiij + Yi,J+1(1−
J∑
j=1
piij)
]
, (10)
where the outer summation is over all individuals in the sample.
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To obtain maximum likelihood estimates of the regression parameters, we maximize (10)
using numerical optimization techniques (discussed in Section 3.3). During optimization,
we must ensure that pii1, . . . , piiJ lie between 0 and 1 and that
∑J
j=1 piij < 1 for all i. The
logit link imposes the constraints that 0 < pii1 < 1 and
∑J
j=1 piij < 1; however, it does not
guarantee that 0 < piij < 1, j = 2, . . . , J . Instead, we impose this set of constraints through
the optimization procedure in the form of non-linear constraints on the coefficients. Further
implications of the constraints are presented in the discussion.
3.2 Conditional Probabilities
We now consider regressions on conditional probabilities in order to estimate endpoint A3,
the intrapartum transmission rate. We begin by considering the case where there are two
visit windows, corresponding to birth and 4 to 8 weeks. To examine the relationship between
a set of predictors, (Xi1, . . . , Xim), and pii2|1− , the probability that subject i tests positive
at the 4 to 8 week visit given he or she tested negative at birth, we define the following
regression model:
g(pii1) = X
′
iβ1
g(pii2|1−) = X ′iβ2|1− ,
where g(·) is a link function that specifies the relationship between the predictors, Xi =
(1, Xi1, . . . , Xim)
′, and the response, through the parameters vectors β1 and β2|1− , each of
length m+1. If we choose the logit link, β2|1− represents the change in the log odds of testing
positive at the 4 to 8 week visit, given a negative result at birth, per one unit increase in
Xil, l = 1, . . . ,m.
We calculate pii2 for use in the log-likelihood as
pii2 = pii2|1− × (1− pii1)
= g−1(X ′iβ2|1−)× (1− g−1(X ′iβ1)). (11)
Maximum likelihood estimates of the regression parameters are obtained by maximizing (10),
with pii1 as in (8) and pii2 as in (11). As for the cumulative model, for this maximization,
probabilities pii1, . . . , piiJ must lie between 0 and 1 and
∑J
j=1 piij must be < 1 for all i. The
logit link imposes constraints that 0 < pii1 < 1 and 0 < pii2|1− < 1 which, together, imply
that 0 < pii2 < 1. Thus, for the conditional model with J = 2, the optimization procedure
9
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requires only that pii1 + pii2 < 1.
More generally, we can link covariates to the probability of testing positive in an interval
given all previous tests were negative by setting
piij = piij|(j−1)− × (1−
j−1∑
k=1
piik),
where
piij|(j−1)− = g−1(X ′iβj|(j−1)−). (12)
3.3 Obtaining MLEs
In Sections 3.1 and 3.2, we derived the log-likelihood equations for the cumulative and
conditional regression models. To obtain maximum likelihood estimates of the regression
parameters, we maximize the log-likelihood equations using numerical optimization tech-
niques. For the analyses presented here, numerical optimization was carried out using a
quasi-Newton algorithm with non-linear constraints on the coefficients. The algorithm is an
efficient modification of Powell’s Variable Metric Constrained WatchDog algorithm, which is
available in SAS PROC NLP (SAS Institute Inc., 2004a). Additional details regarding our
implementation are available upon request.
4 Simulations
We performed simulations to assess the properties of the proposed regression estimators,
first by comparing them to the more commonly used logistic regression approaches for per-
forming adjusted analyses described in Section 1 and, second, by assessing how well they
captured the effect of a treatment on in utero and delivery transmission given potential mis-
classification due to early breastfeeding transmission. We considered the case of two visit
windows, corresponding to birth and 4 to 8 weeks. For each simulated dataset, we randomly
generated a set of covariates for each observation that we used to simulate a subject’s time of
detectable infection. Next, we randomly generated a set of visit times for each observation.
We determined each subject’s observed endpoints by comparing his or her simulated time
of detectable infection to his or her simulated visit times. We considered several scenarios,
allowing for different treatment effects and different visit processes. Results for each scenario
10
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are provided, based on 1000 datasets of 1500 observations each.
4.1 Simulation of Time of Detectable Infection
In this section, we describe how we simulated time of detectable infection, which was used
together with information on visit timing (discussed below) to determine a simulated sub-
ject’s sequence of test results. First, we simulated mode of transmission as either in utero,
during delivery or early breastfeeding. In doing so, we assumed that timing of infection is
subject to the effects of a binary and a continuous predictor. The binary predictor (X1) acts
as a treatment with potentially different effects in utero and in the peripartum period and
was drawn from a Bernoulli distribution with probability 0.5. We simulated the continu-
ous predictor (X2) from a normal distribution with mean 4.3 and standard deviation 0.8 to
mimic the observed distribution of log 10 viral load in the HPTN 024 data.
We simulated mode of transmission under two frameworks, one based on a cumulative
regression model and the other based on a conditional regression model. We calculated
the probabilities of in utero infection, pii1, and perinatal infection, pii1 + pii2, for subject i
according to equations (8) and (9) with β1 = (β10, β11, β12)
′, β2 = (β20, β21, β22)′, and g(·)
taken to be the logit link. We calculated the probability of intrapartum infection, pii2|1− , for
subject i according to equation (12) with β2|1− = (β2|1−,0, β2|1−,1, β2|1−,2)′ and g(·) the logit
link. We used a subject’s probability of perinatal infection (along with his or her probability
of in utero infection) to determine pii2 under the cumulative framework. We determined
pii2 under the conditional framework using a subject’s probability of intrapartum infection,
according to equation (11). To simulate whether a subject became infected in utero, at birth,
or neither, we used a multinomial distribution with probabilities pii1, pii2, and 1− (pii1 +pii2).
We allowed for the imperfect sensitivity of the test by generating the time of detectable
infection. This reflects the fact that an intrapartum transmission is unlikely to be detected
at the birth visit. We generated each subject’s time of detectable infection as number
of days since birth. For subjects who became infected in utero, we assigned a time of
detectable infection equal to zero days. For subjects who became infected during delivery,
we generated time of detectable infection according to a uniform (0,14) distribution. An
upper limit of 14 days was chosen to accommodate the lag time inherent in detecting HIV
infection (Balasubramanian and Lagakos, 2001). We also allowed the simulations to reflect
additional positive test results at the 4 to 8 week visit due to breastfeeding. For subjects
infected neither in utero nor at birth, we generated time of detectable infection according
11
Hosted by The Berkeley Electronic Press
Table 2: Simulation of time of detectable infection for each treatment effect scenario
Cumulative Conditional
Treatment Control Treatment Control
Treatment Effect β11 β21=β2|1−,1 pii1 pii1 + pii2 pii1 pii1 + pii2 pii2|1− pii2|1−
TE 1 -0.55 -0.54 0.03 0.11 0.05 0.18 0.05 0.09
TE 2 -0.55 0.00 0.03 0.18 0.05 0.18 0.09 0.09
TE 3 -0.02 -0.38 0.05 0.13 0.05 0.18 0.06 0.09
TE 4 0.27 -0.27 0.07 0.14 0.05 0.18 0.07 0.09
to an exponential distribution. This added an average of 30 infections to the 0 to 8 week
period for the cumulative model and an average of 32 infections to the 0 to 8 week period
for the conditional model.
We simulated time of detectable infection under four treatment effect scenarios, denoted
TE1 through TE4. Under the cumulative framework, we took (β10, β12, β20, β22) = (-4,
0.25, -2.6, 0.25) for each scenario while under the conditional framework, we took (β10,
β12, β2|1−,0, β2|1−,2) = (-4, 0.25, -3.4, 0.25) for each scenario. The effects of treatment
on in utero, perinatal, and intrapartum transmission, represented by β11, β21, and β2|1−,1
respectively, were allowed to vary across scenarios as described in Table 2. For all scenarios,
we assumed that treatment had the same effect on perinatal transmission (cumulative model)
as on intrapartum transmission (conditional model), that is, we took β21=β2|1−,1. Table
2 also provides the probabilities of in utero, perinatal, and intrapartum transmission for
the treatment and control groups for each treatment effect scenario when the continuous
predictor is taken to be equal to its average value.
4.2 Simulation of Visit Process and Determination of Test Results
In simulating each subject’s visit process, we considered two visit windows, birth and 4 to 8
weeks, and the corresponding periods birth, between birth and 4 to 8 weeks, 4 to 8 weeks,
and after 4 to 8 weeks. We simulated whether or not a subject was tested during each of
these periods using a binomial distribution according to three visit process scenarios, denoted
VP1 through VP3 (Table 3). VP1 corresponds to an analysis that might be done at the end
of a study, when all of the data that are expected have been collected. For VP2, we assumed
that a smaller percentage of subjects are tested at the 4 to 8 week visit and after the 4 to 8
week visit. For VP3, we reduced these percentages even further, as well as the percentage
of subjects tested at birth. VP2 and VP3 were designed to represent interim analyses.
We assigned time of visit as number of days since birth. Time of birth visit was generated
12
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Table 3: Probability tested during/following each visit window for each visit process
Visit Process Birth Between birth and 4-8 weeks 4-8 weeks After 4-8 weeks
VP 1 0.85 0.05 0.75a 0.80
VP 2 0.85 0.05 0.50 0.25
VP 3 0.50 0.05 0.25 0.10
aProbability 0.85 used if infection detected on day 0.
according to a multinomial distribution with probability 0.4 for days 0 and 1 and probability
0.04 for days 2 through 6. For visits between birth and 4 to 8 weeks, time of visit was
assigned according to a multinomial distribution with probability 0.05 for all days. For visits
during the 4 to 8 week visit window, time of visit was assigned according to a multinomial
distribution with probability 0.04 for all days. For visits after 4 to 8 weeks, time of visit was
assigned according to a multinomial distribution, with days 275 through 325 weighted more
heavily (probability = 0.008) than other days in the period (probability = 0.002). Each
subject was allowed at most one visit in each of the windows described.
Finally, we compared each subject’s simulated time of detectable infection to his or her
simulated visit times to generate the subject’s vector of observed results (Y ). In assessing
infection after 4 to 8 weeks, we considered only simulated times of detectable infection before
day 500.
4.3 Methods Evaluated
We estimated the effect of treatment using logistic regression models and the proposed cu-
mulative (CM-CUM) and conditional (CM-COND) censored multinomial regression models.
We considered two sets of logistic models: the first (L-CUM) modeled infection at birth and
infection at 4 to 8 weeks among subjects for whom HIV status at birth and HIV status
at 4 to 8 weeks could be determined and the second (L-COND) modeled infection at birth
and infection at 4 to 8 weeks among subjects known to the HIV negative at birth. The
logistic models were chosen to represent those used in the analysis of PMTCT of HIV. Cox
PH models, although often used, do not specifically address treatment effects on A1-A3 but
instead estimate the average treatment effect over the observation period; therefore, we did
not assess them in our simulations.
For the cumulative and conditional approaches, we compared the effect of treatment as
obtained from the regression model to the “true” effect of treatment according to which
the data were generated. We determined bias, mean squared error (MSE), 95% coverage
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probability (CP), and power for each estimator, averaging across datasets for a given set of
simulations. Because we allowed for imperfect sensitivity and early breastfeeding transmis-
sion, we would not expect to see zero bias in the estimates from our simulations. Our design,
however, allows us to judge how well a data analysis estimates the associations in terms of
how they are interpreted (as in utero, intrapartum, etc.).
In carrying out numerical optimization, we chose the convergence criteria for the proposed
cumulative and conditional regression models to coincide with the convergence criteria for
the logistic regression models in SAS PROC LOGISTIC (SAS Institute Inc., 2004b).
4.4 Simulation Results
Table 4 provides simulation results for the following combinations of treatment effect and
visit process: TE1/VP1, TE2/VP1, TE3/VP1, TE4/VP1, TE4/VP2, and TE4/VP3. These
combinations allow us to assess the impact of treatment effect on estimator performance
for a given visit process as well as the impact of visit process on estimator performance
for a given treatment effect. Table 4 consists of six subtables each corresponding to one of
the above TE/VP scenarios. Results for the estimators of treatment effect at 4 to 8 weeks
(cumulative models) and the estimators of treatment effect at 4 to 8 weeks among infants
with a negative test result at birth (conditional models) are combined under the heading
“4-8 weeks.” Models are denoted using the abbreviations provided in Section 4.3.
We find that the CM-CUM model performs comparably to, or better than, the L-CUM
model across all performance measures, for all but the TE1/VP1 scenario. Here, the birth
estimate obtained from the L-CUM model is less biased than the birth estimate obtained
from the CM-CUM model, although the bias is small in both cases (0.013 versus 0.027,
respectively). In addition, power at birth is slightly higher for the L-CUM model than for
the CM-CUM model. For TE1/VP1, we assumed that treatment reduces the odds of both
in utero and perinatal transmission, and that the effect of treatment on the two endpoints
is roughly the same.
Across all scenarios, MSE is consistently lower (albeit only slightly in most cases) for the
CM-CUM model than for its logistic counterpart. The CPs for the competing cumulative
models are similar while power at 4 to 8 weeks is higher for the CM-CUM model than for the
L-CUM model for all scenarios where power was assessed. In general, we observe that power
for the cumulative models is higher at 4 to 8 weeks than at birth. This is not surprising
given the smaller probability of infection at birth as well as the fact that the simulations
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Table 4: Simulation results for selected treatment effect/visit process scenarios
Bias MSE CP Power
Scenario Birth 4-8 weeks Birth 4-8 weeks Birth 4-8 weeks Birth 4-8 weeks
TE1/VP1
L-CUM 0.013 0.045 0.069 0.030 0.948 0.943 0.518 0.845
CM-CUM 0.027 0.048 0.068 0.027 0.948 0.939 0.499 0.882
L-COND -0.015 0.107 0.077 0.077 0.959 0.914 0.539 0.439
CM-COND -0.007 0.106 0.072 0.072 0.956 0.901 0.541 0.461
TE2/VP1
L-CUM 0.173 -0.020 0.096 0.022 0.879 0.952 0.309 –
CM-CUM 0.168 -0.009 0.094 0.020 0.873 0.952 0.339 –
L-COND 0.098 0.004 0.083 0.050 0.938 0.956 0.398 –
CM-COND 0.101 0.006 0.079 0.046 0.941 0.952 0.405 –
TE3/VP1
L-CUM -0.078 0.055 0.058 0.029 0.952 0.931 0.057 0.517
CM-CUM -0.064 0.049 0.054 0.025 0.954 0.933 0.056 0.605
L-COND -0.050 0.064 0.062 0.059 0.946 0.941 0.062 0.263
CM-COND -0.042 0.063 0.058 0.055 0.944 0.944 0.057 0.264
TE4/VP1
L-CUM -0.123 0.059 0.065 0.028 0.921 0.936 0.096 0.271
CM-CUM -0.105 0.049 0.057 0.023 0.931 0.942 0.111 0.307
L-COND -0.043 0.034 0.058 0.060 0.953 0.937 0.160 0.173
CM-COND -0.038 0.033 0.055 0.056 0.954 0.936 0.186 0.187
TE4/VP2
L-CUM -0.110 0.116 0.064 0.045 0.927 0.898 0.103 0.138
CM-CUM -0.096 0.043 0.059 0.032 0.927 0.940 0.128 0.261
L-COND -0.073 0.041 0.061 0.084 0.941 0.949 0.138 0.123
CM-COND -0.066 0.042 0.054 0.078 0.946 0.945 0.146 0.134
TE4/VP3
L-CUM -0.124 0.192 0.113 0.105 0.923 0.890 0.068 0.064
CM-CUM -0.088 0.017 0.097 0.058 0.939 0.954 0.096 0.193
L-COND -0.054 -0.009 0.099 0.292 0.944 0.967 0.095 0.077
CM-COND -0.040 0.002 0.087 0.211 0.946 0.964 0.102 0.086
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were designed based on HPTN 024, which was powered to detect a difference in cumulative
transmission rates at 4 to 8 weeks.
The CM-CUM model performs most impressively for the TE4/VP1, TE4/VP2, and
TE4/VP3 scenarios, where it consistently outperforms the L-CUM model in terms of bias,
MSE, CP, and power at birth and at 4 to 8 weeks. In addition, as the amount of missing
test result data increases, the improvement offered by the CM-CUM model increases. We
see this, for example, in the bias estimates at 4 to 8 weeks. Recall that VP2 and VP3 were
designed to represent interim analyses, as described in Section 4.2. For TE4/VP1, the bias
for the L-CUM model is 1.2 times the bias for the CM-CUM model. For TE4/VP2, the bias
for the L-CUM model is 2.7 times the bias for the CM-CUM model. For TE4/VP3, which
assumes the highest percentage of missing data of the visit processes considered, the bias
for the L-CUM model is 11.3 times the bias for the CM-CUM model. We note that, of the
treatment effects considered, TE4 is most similar to that observed in HPTN 024.
On the whole, the CM-COND model performs comparably to the L-COND model. MSE
is consistently lower, although again only slightly, for the CM-COND model than for the
L-COND model. While power tends to be low for the conditional models, power at birth
and at 4 to 8 weeks is slightly higher for the CM-COND model than for the L-COND model
for the TE4/VP1, TE4/VP2, and TE4/VP3 scenarios.
In addition to comparing the proposed regression estimators to the more commonly
used logistic regression approaches, our simulations assessed the bias associated with early
breastfeeding transmission when estimating the treatment effect. Breastfeeding transmission
appears to have had little effect on 4 to 8 week estimates of treatment effect, with the
magnitude of most bias estimates at 4 to 8 weeks (for the CM-CUM and CM-COND models)
less than 0.05. We would expect early breastfeeding contamination to bias the treatment
effect to the null, by adding infections to both the treatment and control arms. This is
consistent with our findings of positive bias at 4 to 8 weeks for TE1, TE3, and TE4, where
we assumed the effect of treatment on birth transmission is negative.
5 Example
In this section, we analyzed data from HPTN 024, a multi-site double-blinded placebo con-
trolled trial of antiobiotics to prevent chorioamnionitis and, therefore, perinatal transmission
of HIV. The trial enrolled pregnant, HIV positive women receiving care in hospitals and clin-
ics in Malawi, Tanzania, and Zambia. Women were randomized to receive either treatment or
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placebo. Treatment consisted of two courses of antibiotics, with the first course administered
at enrollment (20 to 24 weeks gestation) and the second at the onset of contractions and/or
premature rupture of membranes. All women and their liveborn infants were offered single
dose nevirapine per the HIV Network for Prevention Trials (HIVNET) 012 protocol (Guay
et al., 1999). Women were followed during their pregnancies, and their infants were followed
postnatally. Visit windows for determining in utero and delivery/early postnatal transmis-
sion in this breastfeeding population were 0 to 48 hours and 4 to 6 weeks, respectively.
Because over half of the visits scheduled to occur between 4 and 6 weeks actually took place
between 6 and 8 weeks, we extended the second visit window to 4 to 8 weeks for analysis
purposes. We also extended the birth visit window to 0 to 7 days.
Recruitment began in July 2001. The trial was monitored for safety and efficacy by the
NIAID Vaccine and Prevention Data and Safety Monitoring Board (DSMB). In February
2003, the DSMB reviewed trial progress in a scheduled interim analysis and concluded that,
while statistical evidence neither established benefit nor harm, the available evidence ruled
out targetted levels of benefit. The DSMB recommended that HPTN 024 stop recruitment
and continue follow-up of enrolled women and infants. Further randomization and distribu-
tion of study drugs was halted at all clinical sites in early March 2003. Additional details
regarding the 024 study are provided by Taha et al. (2006).
For this example, we defined the treatment and control groups as infants born to mothers
randomized to antibiotics who delivered prior to termination of the study drug and infants
born to mothers randomized to placebo or to mothers randomized to antibiotics who de-
livered after termination of the study drug, respectively. Additional covariates of interest
were log maternal viral load, maternal CD4 count, and infant gender. In the birth model,
we adjusted for mother’s use of nevirapine and, in the 4 to 8 week model, for mother’s and
infant’s use of nevirapine. To account for unmeasured differences between hospitals and
clinics, we included study site in both models.
Of 2052 firstborn infants born alive to HIV positive mothers, 1758 had complete data
with respect to the covariates of interest. Of these, 1696 had a test result at some point
during follow-up and were included in the analysis of HIV infection. 1739 had a test result
or are known to have died during follow-up and were, thus, included in the analysis of HIV
infection or death. Descriptive statistics for the 1739 subjects included in the analysis of HIV
infection or death are provided in Table 5. Figure 2 provides the complete testing profile for
the 1758 subjects with complete covariate data, according to treatment group.
We used the proposed regression methods to analyze the outcomes infection and infection
17
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Table 5: Descriptive statistics for 1739 subjects included in analysis of HIV infection or
death
Covariate Treatment Control
Mean/N SD/% Mean/N SD/%
Maternal viral load (1 log10 unit) 4.338 0.836 4.242 0.817
CD4 count (100 units) 3.697 2.067 3.796 2.234
Female 296 47% 566 51%
Mother nevirapine 603 95% 1066 96%
Mother and infant nevirapine 558 88% 1001 90%
1758 firstborn, liveborn, with 
HIV infected mother
(all covariates non-missing)
64 no specimen at birth
641 treatment
19 died prior to birth visit
28 no specimen at 4-6 weeks
17 specimen at 4-6 weeks
577 specimen at birth
77 no specimen at 4-6 weeks
500 specimen at 4-6 
weeks
7 died prior to 4-6 week 
visit
94 no specimen at birth
1117control
20 died prior to birth visit
29 no specimen at 4-6 weeks
(includes 3 deaths between 
birth and 4-6 week visit)
45 specimen at 4-6 weeks
1023 specimen at birth
140 no specimen at 4-6 weeks
883 specimen at 4-6 
weeks
16 died prior to 4-6 week 
visit
Figure 2: HPTN 024 testing profile.
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Table 6: Adjusted odds ratios at birth, 4 to 8 weeks
Risk factor Birth 4-8 Weeks 4-8 Weeks |- Birth
OR 95% CI OR 95% CI OR 95% CI
Infection endpointa
Treatment vs. control 0.691 [0.469, 1.017] 0.987 [0.736, 1.323] 1.404 [0.928, 2.123]
Maternal viral load (1 log10 unit) 2.552 [1.895, 3.437] 2.820 [2.221, 3.579] 2.873 [2.023, 4.082]
CD4 count (100 units) 1.037 [0.939, 1.145] 1.099 [1.015, 1.190] 1.172 [1.033, 1.331]
Female 0.938 [0.658, 1.339] 1.011 [0.764, 1.338] 1.101 [0.733, 1.654]
Mother nevirapine 0.549 [0.248, 1.215]
Mother and infant nevirapine 0.628 [0.387, 1.019] 0.562 [0.262, 1.206]
Infection/death endpointb
Treatment vs. control 0.873 [0.632, 1.205] 1.025 [0.789, 1.332] 1.245 [0.850, 1.825]
Maternal viral load (1 log10 unit) 2.299 [1.786, 2.959] 2.568 [2.086, 3.161] 2.597 [1.895, 3.558]
CD4 count (100 units) 1.043 [0.959, 1.135] 1.098 [1.024, 1.178] 1.175 [1.048, 1.318]
Female 0.883 [0.650, 1.201] 1.066 [0.829, 1.370] 1.336 [0.916, 1.949]
Mother nevirapine 0.221 [0.128, 0.381]
Mother and infant nevirapine 0.452 [0.302, 0.678] 0.546 [0.277, 1.075]
aAnalysis based on 612 treatment and 1084 control.
bAnalysis based on 632 treatment and 1107 control.
or death. We estimated the cumulative odds of infection at 4 to 8 weeks using the cumulative
model of Section 3.1 and the odds of infection at 4 to 8 weeks among infants with a negative
test result at birth using the conditional model of Section 3.2. Results are provided in Table
6.
We found that treatment does not significantly reduce HIV infection at birth, HIV infec-
tion at 4 to 8 weeks, or HIV infection at 4 to 8 weeks among subjects who test negative at
birth. These findings are consistent with those presented by Taha et al., where treatment
was defined based on intent-to-treat and the analysis was limited to women who delivered
prior to study termination. The trend of estimates here is also consistent with that in Taha
et al., suggesting that treatment decreases the odds of infection at birth (OR 0.691, 95% CI
[0.469, 1.017]) while increasing the odds of infection at 4 to 8 weeks among those who test
negative at birth (OR 1.404, 95% CI [0.928, 2.123]). When we defined first positive test or
death at or before a given visit as the endpoint, we observed the same trend in the estimates
of treatment effect as for the infection endpoint, although the trend was slightly weaker in
this case.
Birth estimates in Table 6 were obtained from the conditional regression model. Birth
estimates obtained from the cumulative model were comparable for all covariates except
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mother’s use of nevirapine in the infection or death model. Using the cumulative regression
model, we obtained an odds ratio estimate of 0.326 (95% CI [0.203, 0.524]), which is slightly
higher than the odds ratio estimate obtained from the conditional model. The difference is
likely a consequence of the fact that almost all mothers received nevirapine (95% of mothers
in the treatment group and 96% of mothers in the control group).
6 Discussion
Many statistical techniques are available for estimating PMTCT of HIV while adjusting for
covariates. Among the more commonly used are logistic regression models and Cox propor-
tional hazards models. While these methods are relatively straightforward to implement,
they do not easily accommodate missed or unscheduled visits while allowing for a time-
varying treatment effect. Cox models can be modified to allow the effect of treatment to
depend upon time but do not fully solve the problem of how to handle missed or unscheduled
visits. Interval censored models, which use a subject’s time to last negative test and time
to first positive test to form an interval around his or her (unknown) time of infection, may
better accommodate the missing data, but software is not generally available for regression
with interval censored data unless we are willing to make parametric assumptions about the
distribution of the event times.
Recently, Bang and Spiegelman (2004) proposed a likelihood approach for a dichotomous
outcome to estimate mother to child transmission when infection status is missing for some
infants due to fetal loss. However, this approach does not address all three endpoints of
interest or missing data due to incomplete follow-up. Balasubramanian and Lagakos (2001)
provide methods for estimating the distribution of the timing of in utero and peripartum
transmission in a non-breastfeeding population that accounts for the imperfect sensitivity
of the HIV assay. Because we examine a breastfeeding population and are interested in
categorizing infection timing, this approach would not be suitable. Little and Rubin (2002,
pages 169, 170) describe an approach for maximum likelihood estimation in a multinomial
setting based on the Expectation Maximization (EM) algorithm. With this approach, data
are categorized according to infection timing and missing values are imputed through an
iterative procedure. While it solves the problem of incomplete data, the approach addresses
only single sample estimation.
Here, we propose a censored multinomial approach for estimating PMTCT that accommo-
dates missing test result data, regression on the three outcomes of interest, and time-varying
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treatment effects. Through simulation, we investigated the performance of the estimators
obtained from the more commonly used logistic regression approaches and compared them
to the proposed estimators. We also looked at the robustness of the estimators to contam-
ination of the endpoint due to early breastfeeding transmission. We found that both the
proposed cumulative model and conditional models performed well when compared to their
logistic counterparts. Performance of the proposed cumulative model was particularly strong
under scenarios designed to represent interim analyses. Power for the proposed models was
consistently higher at 4 to 8 weeks, which is to be expected given that the logistic models
used only data for subjects whose endpoints were non-missing or could be imputed based on
subsequent negative tests.
The censored multinomial regression approach is not without limitations. Both the pro-
posed cumulative and the proposed conditional models impose non-linear constraints on the
coefficients, which can complicate interpretation of the estimates if maximization of the like-
lihood occurs on the boundary of the parameter space. In the case of the conditional model,
however, only a single constraint is imposed, which is no more than would be imposed for a
general multinomial model (Agresti, 2002, page 21). In numerous simulations (beyond those
presented here), we saw no evidence of bias due to maximization on the boundary.
Our approach relies on the assumption that missingness is non-informative and, thus, may
be more appropriate for some endpoints (infection/death) than for others (infection). While
valid for breastfeeding populations, our approach does not allow us to separate intrapartum
transmission from early transmission due to breastfeeding. In addition, our approach assumes
that infants are at risk for breastfeeding transmission throughout the postnatal period and,
thus, does not allow for the possibility of weaning during this period. Our approach does
not account for misclassification due to the imperfect sensitivity of testing. However, as we
demonstrated in our simulations, the bias in the 4 to 8 week estimates for the proposed
models is quite small, suggesting that the impact of misclassification and contamination due
to breastfeeding on our estimates of treatment effect is minimal. Finally, our approach does
not provide a mechanism for estimating relative risks, which are often of interest in PMTCT
trials. Our model could easily be adapted to this context through use of a log link or a
complementary log-log link. In this case, valid comparison models would include relative
risk regression models and time-dependent Cox models. To our knowledge, these models
have not been used in the PMTCT setting but would be worthy of further exploration.
Here, we have studied the problem of estimating the effect of treatment on perinatal
mother to child transmission of HIV when outcome data are incomplete. We provide methods
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that give consistent and asymptotically normal estimators using maximum likelihood and
are easily programmed using standard statistical software. Through simulation, we have
shown that the proposed methods outperform standard logistic regression methods in terms
of bias, mean squared error, coverage probability, and power under a range of treatment
effect and visit process scenarios. While demonstrated for HIV transmission, the approach
has broader applicability to problems of estimating treatment effects on disease incidence
when data are collected at multiple visits spaced in time and outcome for some subjects, at
some time points, is unknown.
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